30
Participants
Start Date
September 1, 2025
Primary Completion Date
December 1, 2025
Study Completion Date
December 1, 2026
EF-009
"Subjects who meet the eligibility criteria will have completed following evaluations and assessments before receiving treatment: a) review of medical and medication history; b) physical examination, vital signs and documentation of ECOG; c) ECG; d) routine serum biochemical, hematologic, urine pregnancy (if applicable) and urine laboratory assessments; and e) evaluation of European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 score.~On Day 0, subjects will undergo EF-009 wafer implantation via laparoscopy"
Everfront Biotech Co., Ltd.
INDUSTRY